№ lp_2_3_60311
File format: docx Character count: 61217 File size: 88 KB
Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used as part of a treatment regimen for Type 2 Diabetes Mellitus in combination with insulin and metformin, subject to specific criteria.
Year: 2019
Region / City: Australia
Topic: Type 2 Diabetes Mellitus Treatment
Document Type: Submission for PBS listing
Organization / Institution: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Novo Nordisk Pharmaceuticals Pty Ltd
Target Audience: Medical practitioners, healthcare providers
Period of Validity: Ongoing after approval in 2020
Approval Date: 1 July 2020
Date of Last Modification: 2021
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Cover Letter Submitting “Effectiveness, Adherence, and Safety of Branded Wegovy™ vs. Compounded Semaglutide + Cyanocobalamin (CSC)” to The Journal of Obesity and Metabolism, November 17, 2025
Date: November 17, 2025
Type of document: Cover letter
Manuscript title: Effectiveness, Adherence, and Safety of Branded Wegovy™ vs. Compounded Semaglutide + Cyanocobalamin (CSC)
Article type: Original Article
Journal: The Journal of Obesity and Metabolism
Author: Shanmugesh Raja, MS
Affiliation: University of California, San Francisco
Study design: Retrospective cohort study
Data source: De-identified telemedicine cohort
Interventions studied: FDA-approved semaglutide (Wegovy™) and compounded semaglutide + cyanocobalamin
Outcomes assessed: Weight-loss magnitude and milestones, treatment adherence and persistence, adverse event reporting
Regulatory context: FDA-approved semaglutide compared with compounded formulation
Conflict of interest disclosure: Confirmed disclosed
Prior publication status: Not previously published and not under consideration elsewhere
Is Ozempic Right for You?
Year: 2023
Region / City: Hollywood
Topic: Weight loss, diabetes management
Document Type: Broadcast Script
Organization: OSF HealthCare
Author: Matt Sheehan
Target Audience: Adults with Type 2 Diabetes, people interested in weight loss
Period of Validity: Ongoing
Approval Date: Not specified
Modification Date: Not specified
Ozempic 2.0 weight-loss pill could be game-changer
Year: 2023
Region / City: USA
Topic: Weight-loss drugs
Document Type: News article
Organization / Institution: Breaking News English
Author: Not specified
Target audience: General public
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Topics: Nordisk SEMAGLUTIDE Ozempic